The goal of this application is to exploit the experimental merits of genetically engineered mouse models (GEMMs) of cancer for use in basic and translational cancer science. This application will make use of high refined mouse models of malignant melanoma and prostate cancer harboring signature mutations that are present in the human disease. These models recapitulate the biological, pathological and clinical features of the human disease including metastasis. In Program 1, inducible NRAS* metastatic melanoma model and a high metastatic PTEN/SMAD4 prostate cancer model will be engineered to experience human-like cancer genome instability via incorporation of telomerase deficiency. Using a full range multi-dimensional genome profiling methodologies, we will examine the acquired epigenetic and genetic events in primary and metastatic tumors as well as tumors that have escaped dependence on NRAS* signaling in melanoma or androgen-dependence in prostate cancer. By comparison with human cancer genome atlas profiles, these comparative oncogenomics studies will serve to facilitate the discovery of key driver events in human cancer and understand the nature of these mutational events in the context of metastasis, RAS signaling and androgen dependence. In Program 2, we will utilize our mouse models of metastatic melanoma and prostate cancer to identify metastatic determinants that can predict which early stage tumors are programmed to remain indolent versus pursue an aggressive metastatic course. Specifically, we will take advantage of our GEMMs with differing metastatic potential for each tumor type to develop a metastasis mRNA signature. These murine data will then be interfaced with human DNA copy number data to identify cross-species conserved metastasis-associated genomic events that can then be enlisted into functional validation screens to identify biologically active metastasis determinants. These functional metastasis determinants will be tested in outcome-annotated clinical samples for their predictive value and capacity to guide the optimal clinical management of early stage melanoma and prostate cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
7U01CA141508-04
Application #
8317711
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (M1))
Program Officer
Marks, Cheryl L
Project Start
2009-09-01
Project End
2014-07-31
Budget Start
2012-09-18
Budget End
2013-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$760,324
Indirect Cost
$279,106
Name
University of Texas MD Anderson Cancer Center
Department
Genetics
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kwong, Lawrence N; Chin, Lynda (2014) Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res 74:1814-21
Kwong, Lawrence N; Heffernan, Timothy P; Chin, Lynda (2013) A systems biology approach to personalizing therapeutic combinations. Cancer Discov 3:1339-44
Cheng, Christine S; Rai, Kunal; Garber, Manuel et al. (2013) Semiconductor-based DNA sequencing of histone modification states. Nat Commun 4:2672
Moslehi, Javid; DePinho, Ronald A; Sahin, Ergun (2012) Telomeres and mitochondria in the aging heart. Circ Res 110:1226-37
Ding, Zhihu; Wu, Chang-Jiun; Jaskelioff, Mariela et al. (2012) Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148:896-907
Hu, Jian; Hwang, Soyoon Sarah; Liesa, Marc et al. (2012) Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148:651-63
Sykes, Stephen M; Lane, Steven W; Bullinger, Lars et al. (2011) AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146:697-708
Jaskelioff, Mariela; Muller, Florian L; Paik, Ji-Hye et al. (2011) Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469:102-6
Gan, Boyi; Lim, Carol; Chu, Gerald et al. (2010) FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18:472-84
Gan, Boyi; Hu, Jian; Jiang, Shan et al. (2010) Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468:701-4